Prevalence of premenopausal osteoporosis in hypothyroid patients
DOI:
https://doi.org/10.18203/2349-3933.ijam20200653Keywords:
Levo thyroxine, Osteoporosis, Thyroid stimulating hormone, T-scoreAbstract
Background: Hypothyroidism alone is not a risk factor for osteoporosis but the patient on treatment with levothyroxine in chronic terms have the greater chances of osteoporosis. This study is to evaluate the role of chronic levo-thyroxine treatment on bone mineral density and the development of osteoporosis.
Methods: A cross sectional descriptive study in which patients with recently diagnosed as hypothyroidism were taken as the first group and the second group as those who were having hypothyroidism for more than 2 years plus on chronic treatment with levothyroxine. Healthy premenopausal women were the control group. TSH was measured in all and the T score were used to measure osteoporosis severity. T score of lumbar vertebra and neck of femur were used for comparison. The description of qualitative data was done in absolute frequencies and percentages. The description of quantitative data were done as the, mean standard deviation, median, minimum and maximum. In the comparison of qualitative data between groups, the Chi-square test and contingency tables was used by rearranging the percentages of several variables (TSH, t-score). The statistical significance was set p<0.05.
Results: TSH levels in the first group were slightly different from rest of the groups. T score were significantly lesser in patients in the second group who are diagnosed with hypothyroidism and on treatment with levothyroxine.
Conclusions: The treatment for hypothyroidism with levo thyroxine reduces both TSH and bone mineral density in the study groups. Proper control of risk factors and avoidance of high dose thyroxine supplements are an effective way in prevention of osteoporosis.
References
Harvey CB, O'Shea PJ, Scott AJ, Robson H, Siebler T, Shalet SM, et al. Molecular mechanisms of thyroid hormone effects on bone growth and function. Mol Gene Metab. 2002 Jan 1;75(1):17-30.
Bassett JD, Williams GR. The molecular actions of thyroid hormone in bone. Trends Endocrinol Metab. 2003 Oct 1;14(8):356-64.
Amashukeli M, Giorgadze E, Tsagareli M, Nozadze N, Jeiranashvili N. The impact of thyroid diseases on bone metabolism and fracture risk. Georg Med News. 2010(184-185):34-9.
Ribot C, Tremollieres F, Pouilles JM, Louvet JP. Bone mineral density and thyroid hormone therapy. Clini Endocrinol. 1990 Aug;33(2):143-54.
Eriksen EF, Mosekilde L, Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone. 1985 Jan 1;6(6):421-8.
Florkowski CM, Cramb R. Thyroxine replacement treatment and osteoporosis. BMJ: Br Med J. 1990 Apr 21;300(6731):1075.
Mosekilde L, Eriksen EF, Charles P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol Metab Clini North Am. 1990 Mar 1;19(1):35-63.
Toft AD. Thyroxine replacement treatment: clinical judgment or biochemical control?. Br Medi J (Clini Res ed.). 1985 Jul 27;291(6490):233-4.
Coindre JM, David JP, Rivière L, Goussot JF, Roger P, de Mascarel A, et al. Bone loss in hypothyroidism with hormone replacement: a histomorphometric study. Arch Int Med. 1986 Jan 1;146(1):48-53.
Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16,249 patients. Thyroid. 2002 May 1;12(5):411-9.
Ross DS, Neer RM, Ridgway EC, Daniels GH. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med. 1987 Jun 1;82(6):1167-70.
